Advertisement

Role of TCTP for Cellular Differentiation and Cancer Therapy

  • Ean-Jeong Seo
  • Nicolas Fischer
  • Thomas EfferthEmail author
Chapter
Part of the Results and Problems in Cell Differentiation book series (RESULTS, volume 64)

Abstract

The translationally controlled tumor protein (TCTP) is a highly conserved protein that is regulated due to a high number of extracellular stimuli. TCTP has an important role for cell cycle and normal development. On the other side, tumor reversion and malignant transformation have been associated with TCTP. TCTP has been found among the 12 genes that are differentially expressed during mouse oocyte maturation, and an overexpression of this gene was reported in a wide variety of different cancer types. Its antiapoptotic effect is indicated by the interaction with several proapoptotic proteins of the Bcl-2 family and the p53 tumor suppressor protein. In this article, we draw attention to the role of TCTP in cancer, especially, focusing on cell differentiation and tumor reversion, a biological process by which highly tumorigenic cells lose their malignant phenotype. This protein has been shown to be the most strongly downregulated protein in revertant cells compared to the parental cancer cells. Decreased expression of TCTP results either in the reprogramming of cancer cells into reversion or apoptosis. As conventional chemotherapy is frequently associated with the development of drug resistance and high toxicity, the urge for the development of new or additional scientific approaches falls into place. Differentiation therapy aims at reinducing differentiation backward to the nonmalignant cellular state. Here, different approaches have been reported such as the induction of retinoid pathways and the use of histone deacetylase inhibitors. Also, PPARγ agonists and the activation of the vitamin D receptor have been reported as potential targets in differentiation therapy. As TCTP is known as the histamine-releasing factor, antihistaminic drugs have been shown to target this protein. Antihistaminic compounds, hydroxyzine and promethazine, inhibited cell growth of cancer cells and decreased TCTP expression of breast cancer and leukemia cells. Recently, we found that two antihistaminics, levomepromazine and buclizine, inhibited cancer cell growth by direct binding to TCTP and induction of cell differentiation. These data confirmed that TCTP is an exquisite target for anticancer differentiation therapy and antihistaminics have potential to be lead compounds for the direct interaction with TCTP as new inhibitors of human TCTP and tumor growth.

Keywords

Tumor reversion Histaminic drugs Cell development 

Abbreviations

ADDS

Adenylosuccinate synthase

AIF

Apoptosis-inducing factor

APL

Acute promyelocytic leukemia

ATRA

All-trans retinoic acid

Bcl-2

B-cell lymphoma 2

BMP

Bone morphogenic proteins

CH60

Mitochondrial 60 kDa heat shock protein

CHFR

Checkpoint with forkhead and ring finger domains

COF1

Cofilin-1

ENOA

α-Enolase

ER60

Probable protein disulfide isomerase

ES

Embryonic stem

FABP

Liver fatty acid-binding protein

GTA1

Glutathione S-transferase alpha

HDAC

Histone deacetylase

HSP105

Heat shock protein 105

KCRB

Creatine kinase B

Mcl-1

Myeloid cell leukemia 1

MDM2

Murine double minute 2

MPSS

Megasort and massively parallel signature sequencing

NDKA

Nucleoside diphosphate kinase A

NPM2

Nucleoplasmin 2

Oct4

Octamer-binding transcription factor 4

PDCD6IP

Programmed cell death six-interacting protein

PPARγ

Peroxisome proliferator-activated receptor-γ

PS1

Presenilin 1

RARs

Retinoic acid receptors

RMS

Rhabdomyosarcoma

SAHA

Suberoylanilide hydroxamic acid

SIAH1

Seven in absentia homologue 1

Sox2

Sex-determining region Y-box 2

STAT3

Signal transducer and activator of transcription 3

STI1

Stress-inducible phosphoprotein 1

TACC3

Transforming acidic coiled-coil protein 3

TCTP

Translationally controlled tumor protein

TSAP

Tumor suppressor-activated pathway

VDR

Vitamin D receptor

References

  1. Acunzo J et al (2014) TCTP as therapeutic target in cancers. Cancer Treat Rev 40(6):760–769PubMedCrossRefGoogle Scholar
  2. Amit J et al (2009) Adamantinoma of tibial shaft. J Nepal Med Assoc 48(176):331–334Google Scholar
  3. Amson RB et al (1996) Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia gene. Proc Natl Acad Sci U S A 93(9):3953–3957PubMedPubMedCentralCrossRefGoogle Scholar
  4. Amson R et al (2011) Reciprocal repression between P53 and TCTP. Nat Med 18(1):91–99PubMedCrossRefGoogle Scholar
  5. Amson R, Karp JE, Telerman A (2013a) Lessons from tumor reversion for cancer treatment. Curr Opin Oncol 25(1):59–65PubMedCrossRefGoogle Scholar
  6. Amson R et al (2013b) TPT1/TCTP-regulated pathways in phenotypic reprogramming. Trends Cell Biol 23(1):37–46PubMedCrossRefGoogle Scholar
  7. Amzallag N et al (2004) TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway. J Biol Chem 279(44):46104–46112PubMedCrossRefGoogle Scholar
  8. Askanazy M (1907) Die Teratome nach ihrem Bau, ihrem Verlauf, ihrer Genese und im Vergleich zum experimentellen Teratoid. Verhandlungen der deutschen pathologischen Gesellschaft i 11:39–82Google Scholar
  9. Banerjee P, Chatterjee M (2003) Antiproliferative role of vitamin D and its analogs--a brief overview. Mol Cell Biochem 253(1–2):247–254PubMedCrossRefGoogle Scholar
  10. Barlow JW et al (2006) Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatr Blood Cancer 47(6):773–784PubMedCrossRefGoogle Scholar
  11. Baylot V et al (2012) Targeting TCTP as a New Therapeutic Strategy in Castration-resistant Prostate Cancer. Mol Ther 20(12):2244–2256PubMedPubMedCentralCrossRefGoogle Scholar
  12. Bettoun DJ et al (2002) A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J Biol Chem 277(28):24847–24850PubMedCrossRefGoogle Scholar
  13. Bini L et al (1997) Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18(15):2832–2841PubMedCrossRefGoogle Scholar
  14. Bohnsack BL, Hirschi KK (2004) Nutrient regulation of cell cycle progression. Annu Rev Nutr 24:433–453PubMedCrossRefGoogle Scholar
  15. Bommer UA, Thiele BJ (2004) The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol 36(3):379–385PubMedCrossRefGoogle Scholar
  16. Boyle BJ et al (2001) Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165(4):1319–1324PubMedCrossRefGoogle Scholar
  17. Brenner S et al (2000a) In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs. Proc Natl Acad Sci U S A 97(4):1665–1670PubMedPubMedCentralCrossRefGoogle Scholar
  18. Brenner S et al (2000b) Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat Biotechnol 18(6):630–634PubMedCrossRefGoogle Scholar
  19. Brioudes F et al (2010) Translationally controlled tumor protein is a conserved mitotic growth integrator in animals and plants. Proc Natl Acad Sci U S A 107(37):16384–16389PubMedPubMedCentralCrossRefGoogle Scholar
  20. Brodowicz T et al (1999) Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids. Br J Cancer 80(9):1350–1358PubMedPubMedCentralCrossRefGoogle Scholar
  21. Burgess A et al (2008) Chfr interacts and colocalizes with TCTP to the mitotic spindle. Oncogene 27(42):5554–5566PubMedCrossRefGoogle Scholar
  22. Cans C et al (2003) Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc Natl Acad Sci U S A 100(24):13892–13897PubMedPubMedCentralCrossRefGoogle Scholar
  23. Chambers I et al (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113(5):643–655PubMedCrossRefGoogle Scholar
  24. Chen SH et al (2007a) A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol Biol Cell 18(7):2525–2532PubMedPubMedCentralCrossRefGoogle Scholar
  25. Chen Z et al (2007b) The expression of AmphiTCTP, a TCTP orthologous gene in amphioxus related to the development of notochord and somites. Comp Biochem Physiol B Biochem Mol Biol 147(3):460–465PubMedCrossRefGoogle Scholar
  26. Chou M et al (2016) A translationally controlled tumor protein gene Rpf41 is required for the nodulation of Robinia pseudoacacia. Plant Mol Biol 90(4–5):389–402PubMedCrossRefGoogle Scholar
  27. Cress WD, Seto E (2000) Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184(1):1–16PubMedCrossRefGoogle Scholar
  28. Crouch GD, Helman LJ (1991) All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. Cancer Res 51(18):4882–4887PubMedGoogle Scholar
  29. Debrock G et al (2003) A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 89(8):1409–1412PubMedPubMedCentralCrossRefGoogle Scholar
  30. Donovan PJ, Gearhart J (2001) The end of the beginning for pluripotent stem cells. Nature 414(6859):92–97PubMedCrossRefGoogle Scholar
  31. Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol Ren Physiol 289(1):F8–28CrossRefGoogle Scholar
  32. Fiucci G et al (2004) Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter. Proc Natl Acad Sci U S A 101(10):3510–3515PubMedPubMedCentralCrossRefGoogle Scholar
  33. Funston G et al (2012) Binding of translationally controlled tumour protein to the N-terminal domain of HDM2 is inhibited by nutlin-3. PLoS One 7(8):e42642PubMedPubMedCentralCrossRefGoogle Scholar
  34. Gachet Y et al (1999) The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J Cell Sci 112(Pt 8):1257–1271PubMedGoogle Scholar
  35. Garattini E, Gianni M, Terao M (2007) Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents. Vitam Horm 75:301–354PubMedCrossRefGoogle Scholar
  36. Gil-Ad I et al (2004) Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors. J Mol Neurosci 22(3):189–198PubMedCrossRefGoogle Scholar
  37. Ginis I et al (2004) Differences between human and mouse embryonic stem cells. Dev Biol 269(2):360–380PubMedCrossRefGoogle Scholar
  38. Gnanasekar M, Dakshinamoorthy G, Ramaswamy K (2009) Translationally controlled tumor protein is a novel heat shock protein with chaperone-like activity. Biochem Biophys Res Commun 386(2):333–337PubMedPubMedCentralCrossRefGoogle Scholar
  39. Graidist P, Phongdara A, Fujise K (2004) Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity. J Biol Chem 279(39):40868–40875PubMedCrossRefGoogle Scholar
  40. Graidist P et al (2007) Fortilin binds Ca2+ and blocks Ca2+-dependent apoptosis in vivo. Biochem J 408(2):181–191PubMedPubMedCentralCrossRefGoogle Scholar
  41. Grommes C, Landreth GE, Heneka MT (2004) Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5(7):419–429PubMedCrossRefGoogle Scholar
  42. Haghighat NG, Ruben L (1992) Purification of novel calcium binding proteins from Trypanosoma brucei: properties of 22-, 24- and 38-kilodalton proteins. Mol Biochem Parasitol 51(1):99–110PubMedCrossRefGoogle Scholar
  43. Hansen LA et al (2000) Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21(7):1271–1279PubMedCrossRefGoogle Scholar
  44. Hershberger PA et al (2001) Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7(4):1043–1051PubMedGoogle Scholar
  45. Hsu YC et al (2007) Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445(7129):785–788PubMedCrossRefGoogle Scholar
  46. Huang ME, Ye YC, Zhao L (1987a) Treatment of acute promyelocytic leukemia by retinoic acid with or without low dose cytosine arabinoside: report of 4 cases. Zhonghua Nei Ke Za Zhi 26(6):330–332. 380PubMedGoogle Scholar
  47. Huang ME et al (1987b) All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J 100(12):949–953PubMedGoogle Scholar
  48. Inoue T, Kamiyama J, Sakai T (1999) Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 274(45):32309–32317PubMedCrossRefGoogle Scholar
  49. Israeli D et al (1997) A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J 16(14):4384–4392PubMedPubMedCentralCrossRefGoogle Scholar
  50. Jain MV et al (2013) Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J Cell Mol Med 17(1):12–29PubMedPubMedCentralCrossRefGoogle Scholar
  51. Kirchhof N et al (2000) Expression pattern of Oct-4 in preimplantation embryos of different species. Biol Reprod 63(6):1698–1705PubMedCrossRefGoogle Scholar
  52. Koziol MJ, Garrett N, Gurdon JB (2007) Tpt1 activates transcription of oct4 and nanog in transplanted somatic nuclei. Curr Biol 17(9):801–807PubMedPubMedCentralCrossRefGoogle Scholar
  53. Koziol MJ, Gurdon JB (2012) TCTP in development and cancer. Biochem Res Int 2012:105203PubMedPubMedCentralCrossRefGoogle Scholar
  54. Kubiak JZ et al (2008) Temporal regulation of embryonic M-phases. Folia Histochem Cytobiol 46(1):5–9PubMedCrossRefGoogle Scholar
  55. Lal S et al (1993) Levomepromazine receptor binding profile in human brain--implications for treatment-resistant schizophrenia. Acta Psychiatr Scand 87(6):380–383PubMedCrossRefGoogle Scholar
  56. Lespagnol A et al (2008) Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ 15(11):1723–1733PubMedCrossRefGoogle Scholar
  57. Leszczyniecka M et al (2001) Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 90(2–3):105–156PubMedCrossRefGoogle Scholar
  58. Li F, Zhang D, Fujise K (2001) Characterization of fortilin, a novel antiapoptotic protein. J Biol Chem 276(50):47542–47549PubMedCrossRefGoogle Scholar
  59. Liang P, Pardee AB (1992) Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257(5072):967–971PubMedCrossRefGoogle Scholar
  60. Liu M et al (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10(2):142–153PubMedCrossRefGoogle Scholar
  61. Liu H et al (2005) Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol 25(8):3117–3126PubMedPubMedCentralCrossRefGoogle Scholar
  62. Luo P et al (2010) Retinoid-suppressed phosphorylation of RARalpha mediates the differentiation pathway of osteosarcoma cells. Oncogene 29(19):2772–2783PubMedCrossRefGoogle Scholar
  63. MacDonald SM et al (1995) Molecular identification of an IgE-dependent histamine-releasing factor. Science 269(5224):688–690PubMedCrossRefGoogle Scholar
  64. Mai A et al (2005) Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25(3):261–309PubMedCrossRefGoogle Scholar
  65. Martirosyan AR et al (2004) Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model. Biochem Pharmacol 68(9):1729–1738PubMedCrossRefGoogle Scholar
  66. Masuda S, Jones G (2006) Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol Cancer Ther 5(4):797–808PubMedCrossRefGoogle Scholar
  67. Masui S et al (2007) Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9(6):625–635PubMedCrossRefGoogle Scholar
  68. Miao X et al (2013) TCTP overexpression is associated with the development and progression of glioma. Tumour Biol 34(6):3357–3361PubMedCrossRefGoogle Scholar
  69. Mitsui K et al (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113(5):631–642PubMedCrossRefGoogle Scholar
  70. Miyamoto K et al (2011) Nuclear actin polymerization is required for transcriptional reprogramming of Oct4 by oocytes. Genes Dev 25(9):946–958PubMedPubMedCentralCrossRefGoogle Scholar
  71. Morrison RF, Farmer SR (1999) Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis. J Biol Chem 274(24):17088–17097PubMedCrossRefGoogle Scholar
  72. Mousset S, Rommelaere J (1982) Minute virus of mice inhibits cell transformation by simian virus 40. Nature 300(5892):537–539PubMedCrossRefGoogle Scholar
  73. Munster PN et al (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61(23):8492–8497PubMedGoogle Scholar
  74. Nagano-Ito M, Ichikawa S (2012) Biological effects of mammalian translationally controlled tumor protein (TCTP) on cell death, proliferation, and tumorigenesis. Biochem Res Int 2012:204960PubMedPubMedCentralCrossRefGoogle Scholar
  75. Nagpal S, Na S, Rathnachalam R (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26(5):662–687PubMedCrossRefGoogle Scholar
  76. Nemani M et al (1996) Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. Proc Natl Acad Sci U S A 93(17):9039–9042PubMedPubMedCentralCrossRefGoogle Scholar
  77. Ng KW et al (1985) Effect of retinoids on the growth, ultrastructure, and cytoskeletal structures of malignant rat osteoblasts. Cancer Res 45(10):5106–5113PubMedGoogle Scholar
  78. Nishimoto M et al (1999) The gene for the embryonic stem cell coactivator UTF1 carries a regulatory element which selectively interacts with a complex composed of Oct-3/4 and Sox-2. Mol Cell Biol 19(8):5453–5465PubMedPubMedCentralCrossRefGoogle Scholar
  79. Niwa H, Miyazaki J, Smith AG (2000) Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24(4):372–376PubMedCrossRefGoogle Scholar
  80. Oh YT et al (2013) Aspergillus nidulans translationally controlled tumor protein has a role in the balance between asexual and sexual differentiation and normal hyphal branching. FEMS Microbiol Lett 343(1):20–25PubMedCrossRefGoogle Scholar
  81. Olsson I et al (1983) Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res 43(12 Pt 1):5862–5867PubMedGoogle Scholar
  82. Pan GJ et al (2002) Stem cell pluripotency and transcription factor Oct4. Cell Res 12(5–6):321–329PubMedCrossRefGoogle Scholar
  83. Passer BJ et al (2003) The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. Proc Natl Acad Sci U S A 100(5):2284–2289PubMedPubMedCentralCrossRefGoogle Scholar
  84. Pesce M, Schöler HR (2001) Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells 19(4):271–278PubMedCrossRefGoogle Scholar
  85. Pierce GB, Wallace C (1971) Differentiation of malignant to benign cells. Cancer Res 31(2):127–134PubMedGoogle Scholar
  86. Platta CS et al (2007) The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res 142(2):219–226PubMedCrossRefGoogle Scholar
  87. Rho SB et al (2011) Anti-apoptotic protein TCTP controls the stability of the tumor suppressor p53. FEBS Lett 585(1):29–35PubMedCrossRefGoogle Scholar
  88. Rigby WF et al (1984) Differentiation of a human monocytic cell line by 1,25-dihydroxyvitamin D3 (calcitriol): a morphologic, phenotypic, and functional analysis. Blood 64(5):1110–1115PubMedGoogle Scholar
  89. Riley T et al (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9(5):402–412PubMedCrossRefGoogle Scholar
  90. Roperch JP et al (1998) Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nat Med 4(7):835–838PubMedCrossRefGoogle Scholar
  91. Roperch JP et al (1999) SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: identification of common effectors with p53 and p21(Waf1). Proc Natl Acad Sci U S A 96(14):8070–8073PubMedPubMedCentralCrossRefGoogle Scholar
  92. Rots NY et al (1998) A differential screen for ligand-regulated genes: identification of HoxA10 as a target of vitamin D3 induction in myeloid leukemic cells. Mol Cell Biol 18(4):1911–1918PubMedPubMedCentralCrossRefGoogle Scholar
  93. Samuel S, Sitrin MD (2008) Vitamin D’s role in cell proliferation and differentiation. Nutr Rev 66(10 Suppl 2):S116–S124PubMedCrossRefGoogle Scholar
  94. Sanchez JC et al (1997) Translationally controlled tumor protein: a protein identified in several nontumoral cells including erythrocytes. Electrophoresis 18(1):150–155PubMedCrossRefGoogle Scholar
  95. Sato N et al (2003) Molecular signature of human embryonic stem cells and its comparison with the mouse. Dev Biol 260(2):404–413PubMedCrossRefGoogle Scholar
  96. Seo EJ, Efferth T (2016) Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy. Oncotarget 7(13):16818–16839PubMedPubMedCentralCrossRefGoogle Scholar
  97. Sertznig P et al (2007) Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 212(1):1–12PubMedCrossRefGoogle Scholar
  98. Sinha P et al (2000) Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 21(14):3048–3057PubMedCrossRefGoogle Scholar
  99. Song X, Norman AW (1998) 1Alpha,25-dihydroxyvitamin D3 and phorbol ester mediate the expression of alkaline phosphatase in NB4 acute promyelocytic leukemia cells. Leuk Res 22(1):69–76PubMedCrossRefGoogle Scholar
  100. Spira AI, Carducci MA (2003) Differentiation therapy. Curr Opin Pharmacol 3(4):338–343PubMedCrossRefGoogle Scholar
  101. Stierum R et al (2003) Proteome analysis reveals novel proteins associated with proliferation and differentiation of the colorectal cancer cell line Caco-2. Biochim Biophys Acta 1650(1–2):73–91PubMedCrossRefGoogle Scholar
  102. Strobl JS et al (1990) Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Cancer Res 50(17):5399–5405PubMedGoogle Scholar
  103. Susini L et al (2008) TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ 15(8):1211–1220PubMedCrossRefGoogle Scholar
  104. Tani T et al (2007) Bovine oocytes with the potential to reprogram somatic cell nuclei have a unique 23-kDa protein, phosphorylated transcriptionally controlled tumor protein (TCTP). Cloning Stem Cells 9(2):267–280PubMedCrossRefGoogle Scholar
  105. Telerman A, Amson R (2009) The molecular programme of tumour reversion: the steps beyond malignant transformation. Nat Rev Cancer 9(3):206–216PubMedCrossRefGoogle Scholar
  106. Telerman A et al (1993) A model for tumor suppression using H-1 parvovirus. Proc Natl Acad Sci U S A 90(18):8702–8706PubMedPubMedCentralCrossRefGoogle Scholar
  107. Thein R, Lotan R (1982) Sensitivity of cultured human osteosarcoma and chondrosarcoma cells to retinoic acid. Cancer Res 42(11):4771–4775PubMedGoogle Scholar
  108. Thurston DE (2007) Chemistry and pharmacology of anticancer drugs. CRC Press/Taylor and Francis Group, Boca RatonGoogle Scholar
  109. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79(7):1147–1156PubMedCrossRefGoogle Scholar
  110. Tontonoz P et al (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 94(1):237–241PubMedPubMedCentralCrossRefGoogle Scholar
  111. Toolan HW (1967) Lack of oncogenic effect of the H-viruses for hamsters. Nature 214(5092):1036PubMedCrossRefGoogle Scholar
  112. Toscano-Morales R et al (2015) AtTCTP2, an Arabidopsis thaliana homolog of Translationally Controlled Tumor Protein, enhances in vitro plant regeneration. Front Plant Sci 6:468PubMedPubMedCentralCrossRefGoogle Scholar
  113. Tsarova K, Yarmola EG, Bubb MR (2010) Identification of a cofilin-like actin-binding site on translationally controlled tumor protein (TCTP). FEBS Lett 584(23):4756–4760PubMedCrossRefGoogle Scholar
  114. Tuynder M et al (2002) Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci U S A 99(23):14976–14981PubMedPubMedCentralCrossRefGoogle Scholar
  115. Tuynder M et al (2004) Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci U S A 101(43):15364–15369PubMedPubMedCentralCrossRefGoogle Scholar
  116. Vitale AM et al (2007) Proteomic profiling of murine oocyte maturation. Mol Reprod Dev 74(5):608–616PubMedCrossRefGoogle Scholar
  117. Wahli W, Braissant O, Desvergne B (1995) Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol 2(5):261–266PubMedCrossRefGoogle Scholar
  118. Wang D, Gao L (2005) Proteomic analysis of neural differentiation of mouse embryonic stem cells. Proteomics 5(17):4414–4426PubMedCrossRefGoogle Scholar
  119. Wang QM, Luo X, Studzinski GP (1997) Cyclin-dependent kinase 6 is the principal target of p27/Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells. Cancer Res 57(14):2851–2855PubMedGoogle Scholar
  120. Waxman S (2000) Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia 14(3):491–496PubMedCrossRefGoogle Scholar
  121. Williams AC et al (1996) In vitro models for studying colorectal carcinogenesis: cellular and molecular events including APC and Rb cleavage in the control of proliferation, differentiation and apoptosis. Biochim Biophys Acta 1288(1):F9–19PubMedGoogle Scholar
  122. Xu A, Bellamy AR, Taylor JA (1999) Expression of translationally controlled tumour protein is regulated by calcium at both the transcriptional and post-transcriptional level. Biochem J 342(Pt 3):683–689PubMedPubMedCentralCrossRefGoogle Scholar
  123. Yan L et al (2000) A cnidarian homologue of translationally controlled tumor protein (P23/TCTP). Dev Genes Evol 210(10):507–511PubMedCrossRefGoogle Scholar
  124. Yang T, Kozopas KM, Craig RW (1995) The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 128(6):1173–1184PubMedCrossRefGoogle Scholar
  125. Yang Y et al (2005) An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene 24(30):4778–4788PubMedPubMedCentralCrossRefGoogle Scholar
  126. Yarm FR (2002) Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol Cell Biol 22(17):6209–6221PubMedPubMedCentralCrossRefGoogle Scholar
  127. Ying QL et al (2003) BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115(3):281–292PubMedCrossRefGoogle Scholar
  128. Zhang D et al (2002) Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and fortilin. The potential role of MCL1 as a fortilin chaperone. J Biol Chem 277(40):37430–37438PubMedCrossRefGoogle Scholar
  129. Zhelev Z et al (2004) Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol 53(3):267–275PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Ean-Jeong Seo
    • 1
  • Nicolas Fischer
    • 1
  • Thomas Efferth
    • 1
    Email author
  1. 1.Department of Pharmaceutical BiologyInstitute of Pharmacy and Biochemistry, Johannes Gutenberg UniversityMainzGermany

Personalised recommendations